Literature DB >> 10951695

Expression and immune recognition of SV40 Tag in transgenic mice that develop metastatic osteosarcomas.

I Marton1, S E Johnson, I Damjanov, K S Currier, J P Sundberg, B B Knowles.   

Abstract

Mature adult mice of the C57BL/6-TgN(Amy1TAg)501Knw transgenic mouse lineage, 501, containing a liver alpha-amylase promoted-SV40 Tag hybrid gene, routinely develop SV40 Tag-induced metastatic osteosarcomas. This form of alpha-amylase was known to be expressed in the liver, salivary glands, pancreas, and fat. Cells in the normal rib adjacent to the periosteum also express alpha-amylase suggesting that transgene expression is correctly targeted to generate osteosarcomas. 501 mice express SV40 Tag in the salivary glands but do not develop abnormalities in these organs by the time of their death from SV40-induced osteosarcomas. Mice of the C57BL/6 strain make a strong and effective anti-tumor immune response to SV40 Tag immunization. However, immunization of 501 mice with SV40 Tag early in life does not alter or prevent SV40 Tag-induced osteosarcomagenesis. 501 mice mount a significantly less effective cytotoxic T-lymphocyte response following SV40 Tag immunization while 501 osteosarcoma-derived cells are fully susceptible to SV40 Tag-specific T-cell lysis. This suggests that partial tolerance, not loss of antigen presentation by tumor cells, characterizes this mouse model of endogenous bone tumor development. To determine whether the immune recognition of endogenous SV40 Tag could influence tumorigenesis, the metastatic potential and time of death from tumor was investigated in CD4-null mutant 501 mice and beta-2 microglobulin-null mutant 501 mice. The size and number of metastases in these strains and longevity of these strains varied. We suggest that components of both the innate and adaptive immune response control tumor appearance and progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951695     DOI: 10.1023/a:1008939620322

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  34 in total

1.  Gene expression during preimplantation mouse development.

Authors:  J L Rothstein; D Johnson; J A DeLoia; J Skowronski; D Solter; B Knowles
Journal:  Genes Dev       Date:  1992-07       Impact factor: 11.361

2.  Cell-mediated cytotoxicity to SV40-specific tumour-associated antigens.

Authors:  G Trinchieri; D P Aden; B B Knowles
Journal:  Nature       Date:  1976-05-27       Impact factor: 49.962

3.  Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen.

Authors:  B B Knowles; M Koncar; K Pfizenmaier; D Solter; D P Aden; G Trinchieri
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

4.  Monoclonal antibody to SV40 T-antigen blocks lysis of cloned cytotoxic T-cell line specific for SV40 TASA.

Authors:  S Pan; B B Knowles
Journal:  Virology       Date:  1983-02       Impact factor: 3.616

Review 5.  Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes.

Authors:  S S Tevethia
Journal:  Mol Biol Med       Date:  1990-02

6.  Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen.

Authors:  T M Wilkie; R A Schmidt; M Baetscher; A Messing
Journal:  Oncogene       Date:  1994-10       Impact factor: 9.867

7.  Lactation-induced WAP-SV40 Tag transgene expression in C57BL/6J mice leads to mammary carcinoma.

Authors:  M R Hüsler; K A Kotopoulis; J P Sundberg; B J Tennent; S V Kunig; B B Knowles
Journal:  Transgenic Res       Date:  1998-07       Impact factor: 2.788

8.  Frequency of SV40-specific cytotoxic T-lymphocyte precursors in two SV40 T-antigen transgenic mouse lines.

Authors:  A Juretic; B B Knowles
Journal:  APMIS       Date:  1991-03       Impact factor: 3.205

9.  Down-regulation of MHC class I antigen in insulinoma cells controlled by the R1 element of the H-2 enhancer.

Authors:  X Ye; A Kralli; R Ge; R P Ricciardi; B B Knowles
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

10.  Simian virus 40 (SV40)-transgenic mice that develop tumors are specifically tolerant to SV40 T antigen.

Authors:  S J Faas; S Pan; C A Pinkert; R L Brinster; B B Knowles
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Primary neoplasms of bones in mice: retrospective study and review of literature.

Authors:  A M Kavirayani; J P Sundberg; O Foreman
Journal:  Vet Pathol       Date:  2011-02-22       Impact factor: 2.221

2.  Generation and characterization of a transgenic mouse model for pancreatic cancer.

Authors:  Qiang Sun; Jie Feng; Xiao-Luan Wei; Rong Zhang; Su-Zhen Dong; Qian Shen; Juan Dong; Hou-Da Li; Ying-He Hu
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

3.  In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.

Authors:  Todd D Schell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

4.  Osteocytes serve as a progenitor cell of osteosarcoma.

Authors:  Joseph L Sottnik; Brittany Campbell; Rohit Mehra; Omid Behbahani-Nejad; Christopher L Hall; Evan T Keller
Journal:  J Cell Biochem       Date:  2014-08       Impact factor: 4.429

5.  Osteosarcomagenesis: modeling cancer initiation in the mouse.

Authors:  Kevin B Jones
Journal:  Sarcoma       Date:  2011-02-20

6.  Serum Antibodies Against Simian Virus 40 Large T Antigen, the Viral Oncoprotein, in Osteosarcoma Patients.

Authors:  Elisa Mazzoni; Ilaria Bononi; Maria S Benassi; Piero Picci; Elena Torreggiani; Marika Rossini; Andrea Simioli; Maria V Casali; Paola Rizzo; Mauro Tognon; Fernanda Martini
Journal:  Front Cell Dev Biol       Date:  2018-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.